16 Jul, 2024

CereVasc Announces Appointments of New Directors

Admin2024-07-18T18:46:24+00:00July 16th, 2024|

Read More

21 May, 2024

Endovascular Shunting for Communicating Hydrocephalus Using a Biologically Inspired Transdural Cerebrospinal Fluid Valved eShunt® Implant

Admin2024-10-15T17:42:20+00:00May 21st, 2024|Tags: Neurosurgery Clinics of North America|

Read More

13 May, 2024

CereVasc Announces $70 Million Series B Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus

Admin2024-05-28T21:41:18+00:00May 13th, 2024|

Read More

20 Dec, 2023

Thirty-Day Hospital Readmission and Surgical Complication Rates for Shunting in Normal Pressure Hydrocephalus: A Large National Database Analysis

Admin2024-10-14T16:29:05+00:00December 20th, 2023|

Read More

03 Oct, 2023

CereVasc Announces 30th Patient Treated in Pilot Studies of the eShunt® System to treat Communicating Hydrocephalus

Admin2023-12-20T22:01:46+00:00October 3rd, 2023|

Read More

26 Sep, 2023

CereVasc eShunt® System Study Data Presented at Congress of Neurological Surgeons Meeting

Admin2023-11-06T22:49:34+00:00September 26th, 2023|

Read More

18 Sep, 2023

CereVasc Receives FDA IDE Approval to Expand its Clinical Study of Patients with Normal Pressure Hydrocephalus Utilizing the Generation 2 eShunt® System

Admin2023-11-06T22:46:27+00:00September 18th, 2023|

Read More

13 Sep, 2023

CereVasc eShunt® System Study Data Presented at the European Society of Minimally Invasive Neurological Therapy (ESMINT) Congress in Marseille

Admin2023-11-06T22:43:59+00:00September 13th, 2023|

Read More

26 Jun, 2023

CereVasc & LianMedical Announce Corporate Partnership

Admin2023-11-06T22:31:47+00:00June 26th, 2023|

Read More

14 Jun, 2023

CereVasc’s Minimally Invasive Central Nervous System Therapy Delivery System Receives Outstanding Presentation Award at American Society of Gene & Cell Therapy Annual Meeting

Admin2023-11-06T22:29:02+00:00June 14th, 2023|

Read More